Kidney diseases
The prevalence of kidney diseases is emerging as a public health problem. Stem cells (SCs),
currently considered as a promising tool for therapeutic application, have aroused
considerable interest and expectations. With self-renewal capabilities and great potential
for proliferation and differentiation, stem cell therapy opens new avenues for the
development of renal function and structural repair in kidney diseases. Mounting evidence
suggests that stem cells exert a therapeutic effect mainly by replacing damaged tissues and
paracrine pathways. The benefits of various types of SCs in acute kidney disease and
chronic kidney disease have been demonstrated in preclinical studies, and preliminary
results of clinical trials present its safety and tolerability.
The priority of Mesenchymal Stem Cells (MSCs) to traffic to the sites of ischemia, hypoxia,
and inflammatory response following injury plays a crucial role in the success of these as
cellular therapy for organ injuries. MSC homing is defined as the arrest of MSCs within the
vasculature of a tissue followed by transmigration across the endothelium. The homing of
MSCs to the injured tissues has been driven by a combination of chemokine release from
the injured tissue and chemokine receptors that are expressed by MSCs
Stem Cell Res Ther. 2020; 11: 249
